Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

long-term condition

- PMLiVE

NICE backs Bayer’s Eylea as first-line BRVO treatment

Recommends visual impairment therapy over current laser treatment

- PMLiVE

Iris Pauporté joins OSE Immunotherapeutics

She becomes clinical project director at the French biotech

Shire Basingstoke

Shire gives up on Momenta-partnered Humira biosimilar

Will fund programme for another 12 months while divesting ongoing activities to Momenta

- PMLiVE

Amgen’s Kyprolis scarred by head-to-head duel with Velcade

Failed to show superior progression-free survival in first-line treatment trials

- PMLiVE

Is there an ROI on KOLs?

Can you measure return on investment (ROI) from compliant, patient-centred skills training for key opinion leaders?

- PMLiVE

Grünenthal research consortium receives €1.5m EU grant

Wins funding for development of efficacy testing in neuropathic pain treatments

- PMLiVE

Novartis’ Ilaris wins three new FDA approvals

Immunotherapeutic expands in rare Periodic Fever Syndrome conditions

- PMLiVE

IBD Oxford MasterClass 2016 harnesses the chemistry between science and clinical practice

Leading Edge, part of the Lucid Group, delivered another successful Oxford MasterClass this year, which attracted over 260 delegates and 60 international inflammatory bowel disease (IBD) faculty, representing Europe, Asia, Australasia...

Lucid Group Communications Limited

- PMLiVE

Artificial Intelligence: the new healthcare algorithm

The age of computers has hugely evolved, and with the emergence of effective machine learning, pattern recognition, and decision-making algorithms, Artificial Intelligence provides a revolutionary new approach to tailored healthcare....

Blue Latitude Health

- PMLiVE

Kite Pharma soars after positive CAR-T data in lymphoma

Looks to become first marketed CAR-T drug as phase II results pave way for US filing

- PMLiVE

Pfizer decides against long-discussed break-up

Says dividing its R&D and generics businesses would disrupt rather than create value

- PMLiVE

Fair to medalling

Generally competent at strategic planning, how can pharma transition from acceptable to exceptional to deliver gold standard performances?

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links